Triple-negative breast cancer molecular subtyping and treatment progress

Li Yin, Jiang-Jie Duan, Xiu-Wu Bian et al. · 2020

Read Triple-negative breast cancer molecular subtyping and treatment progress by Li Yin, Jiang-Jie Duan, Xiu-Wu Bian et al. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-7285581.txt.

Description

Li Yin and colleagues reviewed in 2020 the biology and treatment of triple-negative breast cancer, one of the hardest forms of the disease to treat. This subtype lacks three targets that guide therapy in other breast cancers: the estrogen receptor, the progesterone receptor, and a growth factor receptor called HER2. It tends to grow fast, spread early, and return after treatment.

The authors explain how this cancer is now split into smaller molecular subtypes, each with its own behavior and weak points. They then survey treatment progress, from chemotherapy backbones to newer targeted drugs and immune based approaches matched to those subtypes. For clinicians and patients, the review maps where real progress is being made against a cancer long short on options.

Catalog record

CREATORLi Yin, Jiang-Jie Duan, Xiu-Wu Bian et al.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE75 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPubMed Central

Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC7285581/

Browse the full library · About the Tower of Babel